KYMR
Kymera Therapeutics, Inc.
There isn't enough reported data to score KYMR yet.
KYMR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
KYMR's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
KYMR PE Valuation
KYMR has no meaningful PE right now: it lost money over the past year.
KYMR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect KYMR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
KYMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.63 | -$0.03 |
| Q2 2026 | -$3.25 | +$0.23 |
| Q1 2026 | -$3.58 | -$0.47 |
| Q4 2025 | -$3.69 | -$0.71 |
| Q3 2025 | -$3.60 | -$1.26 |
| Q2 2025 | -$3.48 | -$1.06 |
| Q1 2025 | -$3.11 | -$0.60 |
| Q4 2024 | -$2.98 | -$0.46 |
KYMR lost $3.63 per share over the past year, about the same as its loss the year before.
KYMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $65M | +466% |
| Q1 2026 | $34.4M | +55% |
| Q4 2025 | $2.9M | -61% |
| Q3 2025 | $2.8M | -26% |
| Q2 2025 | $11.5M | -55% |
| Q1 2025 | $22.1M | +115% |
| Q4 2024 | $7.4M | -85% |
| Q3 2024 | $3.7M | -21% |
KYMR's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -116% | +621 points |
| Q1 2026 | -245% | +92 points |
| Q4 2025 | -3411% | -2319 points |
| Q3 2025 | -3347% | -1419 points |
| Q2 2025 | -737% | -538 points |
| Q1 2025 | -337% | +225 points |
| Q4 2024 | -1092% | -1052 points |
| Q3 2024 | -1928% | -712 points |
KYMR's operating margin was −116% last quarter, up 621 points from the same quarter a year ago.
KYMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$78.2M | -$50.9M |
| Q2 2026 | -$54.5M | +$6M |
| Q1 2026 | -$89.3M | -$9.7M |
| Q4 2025 | -$66.9M | -$4.1M |
| Q3 2025 | -$27.3M | +$22.7M |
| Q2 2025 | -$60.6M | -$13M |
| Q1 2025 | -$79.6M | -$32.6M |
| Q4 2024 | -$62.7M | -$59.1M |
KYMR has burned cash in almost every quarter: −$289M over the past year, against −$230M the year before.
KYMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +1.9M shares |
| 1 year | +15% | +12.8M shares |
| 3 years | +71% | +41.7M shares |
| 5 years | +97% | +49.4M shares |
| Available history | +125% | +55.6M shares |
KYMR has 100M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
KYMR Net Leverage
KYMR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
KYMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.8 | Neutral |
| Stochastic | 80.4 | Overbought |
KYMR's weekly RSI is 63 (neutral) and its Stochastic is 80 (overbought).
KYMR PE vs Healthcare Sector
KYMR has no meaningful PE right now: it lost money over the past year.
KYMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $116.6 | 9.1% above |
| 20 week MA | $115.4 | 10% above |
| 50 week MA | $95.2 | 34% above |
| 100 week MA | $69.0 | 84% above |
| 200 week MA | $50.6 | 151% above |
KYMR is in an uptrend: it's above all five of its weekly moving averages, and 151% above its 200-week average.
KYMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.3 | $86.1 | +159% |
| 2021 | $86.1 | $61.8 | -28% |
| 2022 | $61.8 | $26.5 | -57% |
| 2023 | $26.5 | $25.5 | -3.9% |
| 2024 | $25.5 | $40.1 | +58% |
| 2025 | $40.1 | $81.3 | +103% |
| 2026 YTD | $81.3 | $127.2 | +56% |
KYMR's yearly returns have swung widely, from +159% in 2020 to −57% in 2022. It's up 56% so far in 2026.